Clinical Takeaway
In this controlled trial of healthy adults, neither a low nor a high single dose of CBD directly altered cortical excitability compared to placebo, suggesting CBD may not have meaningful intrinsic anti-seizure properties on its own. The clinical benefit seen in epilepsy syndromes like Dravet and Lennox-Gastaut may be driven largely by CBD’s pharmacokinetic interaction with clobazam rather than a direct brain effect. Patients and clinicians should understand that CBD’s role in seizure control likely depends heavily on combination therapy context.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies that CBD’s clinical efficacy in Dravet and Lennox-Gastaut syndromes likely derives from pharmacokinetic interactions with concurrent medications rather than direct effects on neuronal excitability, fundamentally reshaping clinical understanding of its mechanism of action. These findings have immediate implications for dosing strategies and drug interaction management in patients receiving CBD alongside other antiepileptic agents, particularly clobazam. The results establish that previously attributed seizure control and adverse effects may be attributable to altered metabolism of co-administered drugs rather than CBD’s intrinsic pharmacological properties, necessitating reconsideration of CBD monotherapy efficacy in epilepsy management.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover trial challenges a common assumption about CBD’s mechanism in seizure management by demonstrating that CBD itself does not directly suppress cortical excitability in the doses and populations studied, suggesting that its clinical benefit in approved indications like Dravet syndrome may depend more heavily on pharmacokinetic interactions with concurrent medications like clobazam rather than intrinsic anticonvulsant properties. The findings are important for refining our mechanistic understanding, though they apply primarily to healthy volunteers or specific patient populations, and we should avoid over-generalizing to all clinical contexts where CBD is used off-label for seizure disorders. Clinically, this reinforces the importance of understanding drug-drug interactions when prescribing CBD with other antiseizure medications and supports the cautious approach of using CBD as adjunctive rather than monotherapy, particularly in patients already on enzyme-metabolized ASMs where pharmacokinetic synergy may be driving efficacy rather than additive anticonvulsant action.
| |